Denali Therapeutics Inc (DNLI)

$16.6

-0.22

(-1.31%)

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Denali Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 294.12M → 1.26M (in $), with an average decrease of 99.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 183.38M → -119.47M (in $), with an average decrease of 87.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 79.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 314.0%

Performance

  • $16.54
    $16.93
    $16.60
    downward going graph

    0.36%

    Downside

    Day's Volatility :2.3%

    Upside

    1.95%

    downward going graph
  • $15.45
    $33.31
    $16.60
    downward going graph

    6.93%

    Downside

    52 Weeks Volatility :53.62%

    Upside

    50.17%

    downward going graph

Returns

PeriodDenali Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
0.54%
-0.7%
0.0%
6 Months
-12.98%
6.6%
0.0%
1 Year
-33.04%
3.7%
-1.5%
3 Years
-68.32%
14.0%
-21.8%

Highlights

Market Capitalization
2.5B
Book Value
$7.45
Earnings Per Share (EPS)
-1.06
Wall Street Target Price
41.19
Profit Margin
-43.94%
Operating Margin TTM
-59.51%
Return On Assets TTM
-9.41%
Return On Equity TTM
-14.01%
Revenue TTM
330.5M
Revenue Per Share TTM
2.41
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-250.3M
EBITDA
-187.9M
Diluted Eps TTM
-1.06
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.6
EPS Estimate Next Year
-2.59
EPS Estimate Current Quarter
-0.8
EPS Estimate Next Quarter
-0.8

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Denali Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
20
19
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 148.13%

Current $16.60
Target $41.19

Technicals Summary

Sell

Neutral

Buy

Denali Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Denali Therapeutics Inc
Denali Therapeutics Inc
-16.28%
-12.98%
-33.04%
-68.32%
-33.17%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Denali Therapeutics Inc
Denali Therapeutics Inc
NA
NA
NA
-2.6
-0.14
-0.09
NA
7.45
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Denali Therapeutics Inc
Denali Therapeutics Inc
Buy
$2.5B
-33.17%
NA
-43.94%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Baillie Gifford & Co Limited.

    10.25%
  • BlackRock Inc

    8.30%
  • Vanguard Group Inc

    7.79%
  • Wellington Management Company LLP

    5.23%
  • Temasek Holdings Ltd.

    4.96%
  • Crestline Management LP

    4.07%

Corporate Announcements

  • Denali Therapeutics Inc Earnings

    Denali Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).

Organization
Denali Therapeutics Inc
Employees
445
CEO
Dr. Ryan J. Watts Ph.D.
Industry
Health Technology

FAQs